13209-41-1

13209-41-1 structure

Name: Vamorolone
Chemical Name: 16α-Methyl-9,11-dehydro Prednisolone
CAS Number: 13209-41-1
Molecular Formula: C₂₂H₂₈O₄
Molecular Weight: 356.45500
Catalog: Signaling Pathways GPCR/G Protein Glucocorticoid Receptor
Create Date: 2017-07-01 10:58:18
Modify Date: 2024-01-03 10:51:53
Vamorolone (VBP15) is a first-in-class, orally active dissociative steroidal anti-inflammatory drug and membrane-stabilizer. Vamorolone improves muscular dystrophy without side effects. Vamorolone shows potent NF-κB inhibition and substantially reduces hormonal effects[1][2].

Name	16α-Methyl-9,11-dehydro Prednisolone
Synonyms	(8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one

Description	Vamorolone (VBP15) is a first-in-class, orally active dissociative steroidal anti-inflammatory drug and membrane-stabilizer. Vamorolone improves muscular dystrophy without side effects. Vamorolone shows potent NF-κB inhibition and substantially reduces hormonal effects[1][2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Mineralocorticoid Receptor Research Areas >> Inflammation/Immunology Signaling Pathways >> GPCR/G Protein >> Glucocorticoid Receptor
In Vitro	Vamorolone (VBP15) inhibits TNFα-induced pro-inflammatory NF-κB signaling in C2C12 muscle cells at 1 nM or more. Vamorolone binds the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) with similar affinity[1]. Vamorolone (0.1, 1μM; 30 minutes) reduces production of IL1βand CCL5 inflammatory mediators in primary human macrophages[2]. Vamorolone is a first-in-class mineralocorticoid receptor (MR) antagonist/dissociative glucocorticoid receptor (GR) ligand[3].
In Vivo	Vamorolone (5-30 mg/kg; cherry syrup) shows a superior side effect profile compared to pharmacological glucocorticoids in mdx mice[1]. Vamorolone (30 mg/kg; orally; daily for 20 days) reduces CNS Inflammation in murine experimental autoimmune encephalomyelitis[2]. Animal Model: C57BL/6 mice (experimental autoimmune encephalomyelitis)[2] Dosage: 30 mg/kg Administration: Orally; daily for 20 days (starting one day prior to MOG 33-55 peptide immunization and continuing) Result: Reduced CNS inflammation in murine experimental autoimmune encephalomyelitis.
References	[1]. Heier CR, et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med. 2013 Oct;5(10):1569-85. [2]. Dillingham BC, et al. VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis. Cell Mol Neurobiol. 2015 Apr;35(3):377-387. [3]. Heier CR, et al. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance. 2019 Feb 11;2(1). pii: e201800186.

Density	1.24g/cm3
Boiling Point	548.3ºC at 760 mmHg
Molecular Formula	C₂₂H₂₈O₄
Molecular Weight	356.45500
Flash Point	299.4ºC
Exact Mass	356.19900
PSA	74.60000
LogP	2.75290
Vapour Pressure	2.63E-14mmHg at 25°C
Index of Refraction	1.603

Precursor 0
DownStream 1
50-02-2

13209-41-1	1425904-79-5
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
898416-67-6	6906-52-1
899737-45-2	930439-75-1
1018584-77-4	1375289-11-4